Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Atea Pharmaceuticals (AVIR) Return on Capital Employed (2020 - 2026)

Atea Pharmaceuticals' Return on Capital Employed history spans 7 years, with the latest figure at 73.65% for Q1 2026.

  • Quarterly Return on Capital Employed fell 3598.0% to 73.65% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 73.65% through Mar 2026, down 3598.0% year-over-year, with the annual reading at 51.66% for FY2025, 1392.0% down from the prior year.
  • Return on Capital Employed came in at 73.65% for Q1 2026, down from 62.52% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 9.15% in Q1 2022 to a low of 73.65% in Q1 2026.
  • The 5-year median for Return on Capital Employed is 36.12% (2024), against an average of 30.67%.
  • The largest YoY upside for Return on Capital Employed was 519bps in 2022 against a maximum downside of -3827bps in 2022.
  • Atea Pharmaceuticals' Return on Capital Employed stood at 19.85% in 2022, then crashed by -45bps to 28.84% in 2023, then plummeted by -46bps to 42.02% in 2024, then tumbled by -49bps to 62.52% in 2025, then fell by -18bps to 73.65% in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Return on Capital Employed are 73.65% (Q1 2026), 62.52% (Q4 2025), and 47.53% (Q3 2025).